Literature DB >> 10071005

The role of meta-analysis in the regulatory process for foods, drugs, and devices.

J A Berlin1, G A Colditz.   

Abstract

Synthesis of research findings has a long-standing tradition in science. While synthesis is currently required in the US food and drug regulatory process, formal meta-analysis may substitute for a pivotal study or broaden the generalizability of drug efficacy through a preplanned meta-analysis. Preplanned meta-analysis of individual trials with deliberately introduced heterogeneity may maximize the generalizability of results from randomized trials. Combining observational data may help to support an alternative claim or to quantify adverse events. In this setting, methods to address potentially greater sources of bias are required. Overall, meta-analysis adds evidence through the synthesis study findings and permits examination of how treatment effects vary across of subgroups, such as age and sex, and across study settings.

Mesh:

Year:  1999        PMID: 10071005     DOI: 10.1001/jama.281.9.830

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  18 in total

Review 1.  Quantifying adverse drug events : are systematic reviews the answer?

Authors:  Mahyar Etminan; Bruce Carleton; Paula A Rochon
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 2.  Search strategies to identify information on adverse effects: a systematic review.

Authors:  Su Golder; Yoon Loke
Journal:  J Med Libr Assoc       Date:  2009-04

3.  Late adverse events after drug-eluting stent implantation.

Authors:  David F Kong; Eric L Eisenstein; Robert Harrington
Journal:  Curr Cardiol Rep       Date:  2008-07       Impact factor: 2.931

4.  Prior Effective Sample Size in Conditionally Independent Hierarchical Models.

Authors:  Satoshi Morita; Peter F Thall; Peter Müller
Journal:  Bayesian Anal       Date:  2012-09       Impact factor: 3.728

5.  Orphan therapies: making best use of postmarket data.

Authors:  Judith C Maro; Jeffrey S Brown; Gerald J Dal Pan; Lingling Li
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

Review 6.  Key concepts of clinical trials: a narrative review.

Authors:  Craig A Umscheid; David J Margolis; Craig E Grossman
Journal:  Postgrad Med       Date:  2011-09       Impact factor: 3.840

7.  Using systematic reviews and meta-analyses to support regulatory decision making for neurotoxicants: lessons learned from a case study of PCBs.

Authors:  Michael Goodman; Katherine Squibb; Eric Youngstrom; Laura Gutermuth Anthony; Lauren Kenworthy; Paul H Lipkin; Donald R Mattison; Judy S Lakind
Journal:  Environ Health Perspect       Date:  2010-02-22       Impact factor: 9.031

8.  Creation and implementation of a historical controls database from randomized clinical trials.

Authors:  Jigar R Desai; Edward A Bowen; Mark M Danielson; Rajasekhar R Allam; Michael N Cantor
Journal:  J Am Med Inform Assoc       Date:  2013-02-28       Impact factor: 4.497

9.  Medical records-based postmarketing safety evaluation of rare events with uncertain status.

Authors:  Hongyuan Cao; Lisa M LaVange; Joseph F Heyse; T Christopher Mast; Michael R Kosorok
Journal:  J Biopharm Stat       Date:  2013       Impact factor: 1.051

Review 10.  Analysis of social epidemiology research on infectious diseases: historical patterns and future opportunities.

Authors:  Justin M Cohen; Mark L Wilson; Allison E Aiello
Journal:  J Epidemiol Community Health       Date:  2007-12       Impact factor: 3.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.